Tirzepatide is an injectable prescription medication that treats type 2 diabetes and chronic obesity. It works by mimicking two gut hormones at once, making it the first drug in its class to target both pathways simultaneously. Sold under the brand names Mounjaro (for diabetes) and Zepbound (for weight management), tirzepatide is given as a once-weekly shot under the skin using a prefilled pen.
How Tirzepatide Works in the Body
Your gut naturally releases two hormones after you eat: GLP-1 and GIP. Both signal your pancreas to produce insulin when blood sugar rises. Tirzepatide is a synthetic molecule designed to activate the receptors for both of these hormones, earning it the nickname “twincretin.” Older injectable medications like semaglutide (Ozempic, Wegovy) only activate the GLP-1 receptor. Tirzepatide hits both.
This dual action does more than just boost insulin. GLP-1 slows stomach emptying, promotes feelings of fullness, and reduces appetite. GIP works on fat tissue, bone, and the brain in addition to the pancreas. When both hormones are activated together, the insulin response is significantly stronger than when either one works alone, and the effect on blood sugar control is greater than what GLP-1 drugs achieve by themselves. Animal studies showed the combination also produced larger reductions in body weight, food intake, and fat mass compared to GLP-1 drugs at equivalent doses.
The appetite-suppressing effects are a big part of why tirzepatide causes weight loss. People feel full sooner, eat less, and experience fewer food cravings. The slowed gastric emptying also means food sits in the stomach longer, which contributes to that sense of satiety between meals.
What It’s Approved to Treat
The FDA has approved tirzepatide for two distinct uses under two brand names. Mounjaro is approved alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) who also have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Both versions contain the same active ingredient at the same doses.
Blood Sugar and Weight Loss Results
In the SURPASS-1 clinical trial, published in The Lancet, people with type 2 diabetes who took tirzepatide saw their HbA1c (a measure of average blood sugar over roughly three months) drop by 1.87 to 2.07 percentage points depending on dose, compared to essentially no change with placebo. To put that in perspective, an HbA1c reduction of even 1 percentage point is considered clinically meaningful. The highest dose, 15 mg, brought the average reduction past 2 full points.
Weight loss results have been equally striking. In the SURMOUNT trials studying tirzepatide for obesity, participants who lost enough weight to shift into a lower BMI category also showed significant improvements in waist circumference, fasting insulin, blood sugar, blood pressure, and cholesterol. These cardiometabolic improvements suggest benefits beyond the scale, though long-term cardiovascular outcome data is still being studied.
Dosing and Titration Schedule
Tirzepatide starts at 2.5 mg once per week. This initial dose is not the treatment dose. It’s designed to let your body adjust and minimize side effects. After four weeks, the dose increases to 5 mg weekly. From there, if more blood sugar control or weight loss is needed, your prescriber can raise the dose in 2.5 mg steps every four weeks or longer. The maximum dose is 15 mg once weekly.
This gradual ramp-up matters. Most of the gastrointestinal side effects people experience happen during dose increases, and a slower titration gives the body time to adapt.
How to Use and Store the Pen
Tirzepatide comes in a prefilled pen that you inject under the skin of your stomach, thigh, or upper arm. You pick one day of the week and inject on that same day each week. The injection site should be rotated to avoid skin irritation.
Unused pens need to stay refrigerated between 2°C and 8°C (about 36°F to 46°F) and should be kept away from light. Never freeze them. Once you start using a pen, it can stay at room temperature (up to 30°C or 86°F) for up to 30 days. After 30 days, discard the pen even if medication remains. You can also move a pen back and forth between the refrigerator and room temperature during that 30-day window without affecting the medication’s quality.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent side effects. A meta-analysis pooling data from multiple clinical trials found the following rates among people taking tirzepatide:
- Nausea: about 20% of users, compared to roughly 10% on placebo or other comparators
- Diarrhea: about 16% of users, compared to roughly 9% on comparators
- Vomiting: about 9% of users, compared to roughly 5% on comparators
These symptoms tend to be worst during the first few weeks and after each dose increase. For most people, they ease as the body adjusts. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help. Some people find that the nausea is mild enough to tolerate, while others may need a longer period at a lower dose before stepping up.
Safety Warnings
Tirzepatide carries a boxed warning (the most serious type of FDA warning) about a potential risk of medullary thyroid carcinoma, a rare type of thyroid cancer. This warning exists because drugs in this class caused thyroid tumors in rodent studies. Whether this translates to a real risk in humans remains uncertain, but tirzepatide should not be used by anyone with a personal or family history of medullary thyroid cancer or a condition called Multiple Endocrine Neoplasia syndrome type 2.
Other safety concerns include the risk of low blood sugar when combined with insulin or certain other diabetes medications, possible worsening of diabetic eye disease in some cases, and rare reports of pancreatitis. People with a history of severe gastrointestinal disease should discuss risks with their prescriber before starting.
Current Availability
As of early 2026, tirzepatide does not appear on the FDA’s drug shortage list. Earlier supply constraints that had affected availability and driven demand for compounded versions have largely stabilized. Both Mounjaro and Zepbound are commercially available through standard pharmacies, though cost and insurance coverage vary significantly depending on the indication and your plan.